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Abstract
Background: Malaria rapid diagnostic tests (RDTs) are appropriate for case management, but persistent antigenaemia
is a concern for HRP2-detecting RDTs in endemic areas. It has been suggested that pan-pLDH test bands
on combination RDTs could be used to distinguish persistent antigenaemia from active Plasmodium falciparum
infection, however this assumes all active infections produce positive results on both bands of RDTs, an assertion that
has not been demonstrated.
Methods: In this study, data generated during the WHO-FIND product testing programme for malaria RDTs was reviewed
to investigate the reactivity of individual test bands against P. falciparum in 18 combination RDTs. Each product was tested
against multiple wild-type P. falciparum only samples. Antigen levels were measured by quantitative ELISA for HRP2, pLDH
and aldolase.
Results: When tested against P. falciparum samples at 200 parasites/μL, 92% of RDTs were positive; 57% of these on
both the P. falciparum and pan bands, while 43% were positive on the P. falciparum band only. There was a relationship
between antigen concentration and band positivity; ≥4 ng/mL of HRP2 produced positive results in more than 95% of
P. falciparum bands, while ≥45 ng/mL of pLDH was required for at least 90% of pan bands to be positive.
Conclusions: In active P. falciparum infections it is common for combination RDTs to return a positive HRP2 band
combined with a negative pan-pLDH band, and when both bands are positive, often the pan band is faint. Thus active
infections could be missed if the presence of a HRP2 band in the absence of a pan band is interpreted as being caused
solely by persistent antigenaemia.
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Background
Antigen-detecting malaria rapid diagnostic tests (RDTs)
are an important tool for fever case management and
routine malaria surveillance. Available malaria RDTs can
detect Plasmodium falciparum only, Plasmodium vivax
only, all human Plasmodium species or a combination of
species. Combination RDTs typically contain two test
bands: a P. falciparum-specific test band using either
bound anti-histidine rich protein 2 (HRP2) or anti-P.
falciparum specific plasmodium lactate dehydrogenase
(Pf-pLDH) monoclonal antibodies (Mabs), while the
other test band typically detects either all four human
Plasmodium species (bound anti-pan specific pLDH or
anti-aldolase Mabs) or is species-specific for non-falciparum
malaria (against one or more Plasmodium species).
Many studies have reported the performance of HRP2
and pLDH-based RDTs for detecting P. falciparum mainly
compared to microscopy, as the reference standard [1]. A
systematic review of 48 studies describing malaria
diagnostic performance that accounted for the imperfect
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reference standard indicated that although performance
varied by species, parasite density and immunity, overall
HRP2-detecting RDTs outperformed pLDH-based RDTs
and microscopy with high sensitivity and specificity for
diagnosing malaria in clinical cases in endemic settings,
and also asymptomatic malaria infections in endemic
areas [2]. However, HRP2-detecting RDTs are unsuitable
for monitoring parasite clearance following anti-malarial
treatment due to the persistence of the PfHPR2 antigen in
the blood for up to four or five weeks following curative
treatment of an infection [1-3].
The issue of persistent antigenaemia in endemic areas
has been raised as a factor leading to reduced specificity
of HRP2-detecting RDTs for diagnosing acute malaria
and over-estimates of malaria prevalence in community
surveys [4,5]. Some studies compare HRP2-detecting
RDTs to polymerase chain reaction (PCR) and/or
microscopy results to distinguish between persistent
antigenaemia, and acute infection; and alternatively, it
has been suggested that because pLDH is metabolized
after three to five days following anti-malarial therapy,
that pan-pLDH test bands on combination RDTs could
be used to distinguish between persistent antigenaemia
(following treatment), and active infection [6]. However,
this interpretation is contrary to manufacturers’ instructions
for HRP2 and pan-pLDH or aldolase-based, combination
RDTs, which define a P. falciparum infection as either a
single HRP2 test line reaction or both HRP2 and pan-test
line reactions. Ultimately, any modification to manu-
facturers’ recommendations would only be valid if it
can be shown that active infections do not produce the
same result (HRP2 test line positive only) as post-treatment
antigenaemia.
To investigate the relationships between HRP2 and
pan band positivity, the current study analyses the
individual band reactivity of 18 P. falciparum/pan
combination RDT products against samples collected
from patients with active P. falciparum infection and
without history of anti-malarial therapy in the past
month. The relationship between test band positivity and
antigen concentration in these samples is also described
to help explain the observed results.
Methods
In 2008, an evaluation program to assess the performance
of commercially available malaria RDTs was launched by
the Western Pacific Regional Office of the World
Health Organization (WHO), the Special Programme
for Research and Training in Tropical Diseases (TDR)
and the Foundation for Innovative New Diagnostics
(FIND). Across the first five rounds of product testing
conducted between 2008 and 2013, this programme
has assessed a total of 210 RDT products, including
63 independent combination products to detect and
differentiate P. falciparum and non-P. falciparum species
(hereafter referred to as Pf + pan products). Data generated
during this product testing provides a unique opportunity
to assess and compare the performance of RDTs as well as
individual test bands on well characterized P. falciparum
clinical samples.
The full testing protocol is described elsewhere [7].
The specific focus here in is on the results of testing
each RDT product against a panel of approximately 100
P. falciparum wild-type parasites at 200 and 2,000 or
5,000 parasites/μL. Over the five rounds of testing a total
of 157 parasite samples have been used in these wild-type
panels. Each parasite sample was confirmed by PCR to be
a mono-infection with P. falciparum, and to contain the
gene encoding for the PfHRP2 protein. Patients were
excluded if they had received any form of anti-malarial
therapy in the four weeks preceding enrolment. Antigen
levels of each sample were measured by quantitative
ELISA for HRP2, pLDH and aldolase [7].
Although a total of 63 Pf + pan products have been
tested by the programme, only 18 currently meet the
WHO recommended criteria for procurement of malaria
RDTs: products that have been tested within the last five
years and have high rates of detection (>75% panel
detection score) of both P. falciparum and P. vivax at
200 parasites/μL, and low false positive (<10%) and
invalid (<5%) rates [8]. Of these 18 products, the large
majority (15) use HRP2 as the target P. falciparum band
antigen and pan-pLDH as the target antigen for the pan
band (Table 1). Raw data for these 18 products was
extracted from the full product testing results database for
analysis in the current study.
Each product was tested on each P. falciparum sample
a total of six times; four times using the sample diluted
to 200 parasites/μL and two times using the sample at
2,000 or 5,000 parasites/μL. For each test the band
intensity of the control and test bands were graded on a
visual scale between 0 and 4 using standard colour
charts at the minimum read time recommended by the
manufacturer. These results are the basis of this analysis
with a band intensity of 0 being classified as negative
and intensities of 1, 2, 3 or 4 being classified as positive.
Any tests which returned a negative result on the control
band were classified as invalid and excluded from all
analysis. The overall test result was interpreted according
to the manufacturer instructions:
1. a positive P. falciparum test band (hereafter referred
to as the Pf band) was classified as a positive test for
P. falciparum, irrespective of the result on the pan
test band,
2. a positive result on the pan band when the Pf band
was negative was classified as a positive test
indicating a non-falciparum infection, and
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3. a negative result on both test bands was classified
as a negative test result indicating no Plasmodium
infection.
Since all samples used during testing were known to
contain only P. falciparum parasites, tests positive for a
non-falciparum infection were classified as false positives
(non-P. falciparum).
Statistical analysis
The statistical analysis was conducted using SPSS
Statistics Version 21 (IBM). For RDTs testing positive
to P. falciparum the mean HRP2 band intensities of
tests with a positive pan band were compared to
those with a negative pan band using a paired t-test, with
the RDT product used as the basis for pairing. Pearson’s
correlation was used as the measure of association between
HRP2 and pLDH antigen levels within parasite samples.
Results
Test and band positivity
A total of 7,160 and 3,580 tests were conducted
using the 18 RDT products and P. falciparum sam-
ples containing 200 parasites/μL and 2,000 or 5,000
parasites/μL, respectively. These tests yielded 7,146 and
3,574 valid RDT results for the low and high parasite
concentrations, respectively.
When tested against 200 parasites/μL, 92.3% of the
tests returned a positive result for P. falciparum, 0.9%
returned a false positive result for a non-falciparum
infection and 6.7% of tests were negative. Of the tests
that were positive for P. falciparum infection using
the low parasite density samples, 57.1% were positive
on both the Pf and pan bands, while 42.9% were positive
on the Pf band only. The proportion of tests positive for P.
falciparum varied between individual RDT products (range
81.8% to 96.9%, Figure 1). There was also considerable
product variability in the proportion of positive RDTs with
a positive pan band (range 25.0% to 95.9%, Figure 1).
When tested using parasites at the higher concentration
of 2,000 or 5,000 parasites/μL, 99.7% of tests were positive
for P. falciparum with 96.7% of these tests returning a
positive Pf and pan band. False positive results for a non-
falciparum infection occurred in 0.2% of tests, while 0.1%
of tests were negative for Plasmodium.
Band intensities
The mean band intensity for tests positive on the Pf
band at 200 parasites/μL was 2.47 (standard deviation
(sd) 0.96) for the HRP2-detecting Pf bands and 2.84
(sd 1.03) for PfpLDH-detecting Pf bands. In contrast,
the mean intensity for positive pan bands was lower
at 1.50 (sd 0.78), with 65% of tests having a pan band
intensity of 1. All band intensities increased when products
Table 1 Combination RDT products included in this study
Product Manufacturer P. falciparum
band antigen
Pan band
antigen
No. Pf
samplesa
Advantage Malaria Pan + Pf Card - IR231025 J. Mitra & Co. Pvt. Ltd. HRP2 Pan(pLDH) 100
BIOCREDIT Malaria Ag Pf/Pan (HRPII/pLDH) - C30RHA25 RapiGEN INC. HRP2 Pan(pLDH) 100
BIONOTE MALARIA P.f.& Pan Ag Rapid Test Kit - RG19-08 Bionote,Inc. HRP2 Pan(pLDH) 99
BioTracer™ Malaria Pf/PAN Rapid Card - 17012 Bio Focus Co., Ltd. HRP2 Pan(pLDH) 100
CareStart™ Malaria/Pregnancy Combo - G0221 (pLDH/HRP2/HCG) Access Bio, Inc. HRP2 Pan(pLDH) 99
CareStart™ Malaria HRP2/pLDH (Pf/PAN) COMBO - G0131 Access Bio, Inc. HRP2 Pan(pLDH) 100
CareStart™ Malaria pLDH 3 Line Test - G0121 Access Bio, Inc. Pf(pLDH) Pan(pLDH) 99
CareStart™ Malaria Screen - G0231 Access Bio, Inc. HRP2 / Pf(pLDH) Pan(pLDH) 99
DIAQUICK Malaria P.f/Pan Cassette - Z11200CE DIALAB GmbH HRP2 Pan(pLDH) 100
EzDxTM Malaria Pan/Pf Rapid Test Detection kit - RK MAL 001 Advy Chemical (Affiliate of
Bharat Serums & Vaccines Ltd.)
HRP2 Pan(pLDH) 100
HiSens Malaria Ag Pf/Pv (HRP2/pLDH) Card - HR2923 HBI Co., Ltd. HRP2 Pan(pLDH) 100
Humasis Malaria P.f/Pan Antigen Test - AMAL-7025 Humasis, Co., Ltd. HRP2 Pan(pLDH) 100
Malaria Pf/Pan One Step Rapid Test - RT 20222 Zhejiang Orient Gene Biotech Co., Ltd. HRP2 Pan(pLDH) 100
NanoSign Malaria pf/pan Ag 3.0 - RMAP10 Bioland Ltd. HRP2 Pan(pLDH) 98
OnSite Pf/Pan Ag Rapid Test - R0113C CTK Biotech, Inc. HRP2 Pan(pLDH) 100
ParaHIT - Total Ver. 1.0 (Device) - 55IC204-10 Span Diagnostics Ltd. HRP2 Aldolase 98
SD BIOLINE Malaria Ag P.f/Pan - 05FK60/05FK63 Standard Diagnostics Inc. HRP2 Pan(pLDH) 100
SD BIOLINE Malaria Ag P.f/Pan - 05FK66 Standard Diagnostics Inc. HRP2 Pan(pLDH) 98
aNumber of P. falciparum samples included in the wild type testing panel.
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were tested using samples containing 2,000 or 5,000
parasites/μL; mean band intensities were 3.68 (sd 0.63),
3.91 (sd 0.32) and 2.43 (sd 0.98) for the HRP2-detecting
Pf bands, PfpLDH-detecting Pf bands and the pan bands,
respectively. At this higher parasite density 16.1%, 42.0%,
23.5% and 18.4% of RDTs returning positive results on
both test bands had pan band intensities of 1, 2, 3 and 4,
respectively.
A direct comparison of the pan and Pf band intensities of
individual tests at the lower parasite density revealed that in
0.9%, 12.7% and 86.4% of tests the pan band had a greater,
the same, or less intensity than the Pf band, respectively.
For the 5,720 tests which had a higher Pf band intensity
compared to the pan band intensity, the difference in band
intensities was one unit for 39.2% of tests, two units in
37.8% of tests and three units in 19.1% of tests.
The mean band intensities for positive RDTs with
HRP2-detecting bands varied by product with values
ranging from 1.98 (BioTracer™ Malaria Pf/PAN Rapid
Card - 17012) to 3.21 (BIONOTE MALARIA P.f.& Pan
Ag Rapid Test Kit - RG19-08) when tested against 200
parasites/μL (Figure 2). Product means were approximately
normally distributed around the overall mean of 2.47. The
mean intensities for positive pan bands also varied by
product ranging from 1.01 (EzDx RK MAL 001) to
2.26 (Carestart G0231), but the distribution was positively
skewed with 50% of the products having a mean
band intensity less than 1.19 and only three products
(Carestart G0221, Carestart G0121 and Carestart G0231)
having means greater than 2.1.
A more focused analysis of band intensity was conducted
for RDTs with a HRP2-detecting Pf band using the results
of testing with samples containing 200 parasites/μL. For
each product the mean and distribution of the Pf band
intensity was calculated for tests that were positive on both
the Pf and pan bands and those that were positive only on
the Pf band (Figure 3). Comparison of the mean values re-
vealed that on average, the Pf band intensity for a product
was 0.73 units (95% CI: 0.53-0.93 units) higher when both
the Pf and pan bands were positive (mean = 2.71, sd 0.39)
compared to those where only the Pf band was positive
(mean = 1.97, sd 0.48) (paired t-test, t16 = −7.63, p < 0.001).
Relationship of antigen concentrations in wild-type
Plasmodium falciparum samples and positivity of test bands
The P. falciparum samples used in the testing of the 18
RDTs had varying antigen concentrations. When the
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Figure 1 Performance of individual test bands of RDT products when tested using wild-type P. falciparum parasites at densities of 200
parasites/μL and 2,000 parasites/μL.
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Figure 2 Mean band intensities for 18 RDT products when tested
against wild-type P. falciparum parasites at 200 parasites/μL. The
overall distribution of the Pf and pan band intensity is illustrated by the
corresponding box plot; box extends from first to third quartile, with
line indicating median.
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data for both the low parasite density (200 p/ul) and the
high density (2,000 or 5,000 p/ul) samples were pooled,
the HRP2 concentrations ranged from 0.62 ng/mL to
820.2 ng/mL, while pLDH concentrations ranged from
0.19 ng/mL to 1,800 ng/mL (Figure 4). The HRP2 and
pLDH concentrations within individual samples were
significantly correlated (r = 0.45, p < 0.001).
There was a clear relationship between antigen con-
centration and band positivity rate (Figure 5). With
the exception of two samples, HRP2 concentrations of
4 ng/mL or greater produced positive results in over 95%
of HRP2-detecting test bands. Below this threshold the
test band positivity was highly variable showing a rapid
decline with concentration.
A similar pattern was observed for pLDH and
pLDH-detecting test bands; pLDH concentrations above
45 ng/mL returned positive pLDH test bands in over 90%
of tests. Below this threshold the positivity of the pLDH
test bands declined with concentration (Figure 5).
Discussion
The HRP2 antigen is known to persist within the circula-
tion following curative treatment and this has led to the
suggestion that HRP2-detecting RDTs have reduced speci-
ficity to detect active malaria infection in moderate to high
transmission areas. On the other hand, pLDH is metabo-
lized more quickly and, therefore, RDTs detecting this
enzyme are expected to revert to negative more quickly
following malaria treatment. Therefore, a tempting strat-
egy to differentiate past, treated infections from current
infections is to use combined HRP2 and pan detecting
RDTs, or RDTs that contain separate HRP2 and Pf-pLDH
test bands. While this approach initially sounds reasonable
in circumstances where a recent infection has occurred
[9], its general application to clinical management of fever
cases is subject to discussion. Hawkes et al. [6] conclude
that requiring positivity of both the HRP2 and pLDH
bands in a combination RDT can improve diagnostic
specificity for falciparum malaria in a sub-Saharan African
context, by excluding false positive HRP2 results due to
persistent antigenaemia. This conclusion was reached
after comparing RDT results to microscopy in a sample of
children under five years of age hospitalized for febrile
illness. While this suggestion may be appropriate for
selection of individuals for clinical trials, the extension of
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Figure 3 Distribution of Pf band intensities for HRP2-detecting combination RDTs returning a positive result against samples
containing 200 P. falciparum parasites/μL. Tests are grouped based on whether the pan band was positive (left) or negative (right) in the
individual tests.
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P. falciparum samples (at all dilutions) used for testing RDTs.
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this to clinical diagnosis or management is questionable
since this conclusion is based on the assumption that
all RDTs that are HRP2-positive but pLDH-negative
represent persistent antigenaemia. Underpinning this
assumption is the premise that all current infections
produce positive results on both the HRP2 and pLDH
bands of the RDTs, an assertion that has not been
tested previously in a systematic way for multiple
RDT products.
To address this gap this study analysed data generated
during the WHO-FIND product testing programme for
malaria RDTs with a specific focus on the reactivity
of individual test bands in 18 combination malaria
RDTs that meet the current WHO recommended pro-
curement criteria. Seventeen of these products used
PfHPR2 for the detection of P. falciparum. During
WHO-FIND product testing, these 18 products were
able to consistently detect >75% of the wildtype P.
falciparum and P. vivax samples at a dilution of 200
parasites/μL with low false positive rates or incorrect
species identification. Although this study focused on
the detection of P. falciparum, the RDTs selected for
inclusion in this analysis were purposely restricted to
those meeting the criteria for both P. falciparum and
P. vivax detection to be assured that the pan test bands
were performing well when interpreted according to the
manufacturer’s instructions. This removes the possibility
that the results observed in this study were caused by a
dysfunctional pan band.
The results of the current analysis indicate that there
is a difference in the sensitivity of the HRP2-detecting
test bands and pan-pLDH test bands in the detection of
active infection. At low parasite densities it was observed
that the HRP2-detecting band returned a positive result
in the absence of a positive pan band in over 40% of
positive tests, with this percentage being product specific.
This trend was less evident at higher parasite densities
where both bands tended to be positive simultaneously.
This result matches that previously reported for the SD
BIOLINE Malaria Ag P.f/Pan (catalogue number 05FK60,
Standard Diagnostics Inc., South Korea) product where
the proportion of tests positive on both the HPRP2 and
pLDH bands progressively increased with parasite
density from 6.7% at <100 parasites/μL to 98.5% at >1000
parasites/μL [10]. Similar patterns were also reported for
the SD Malaria Antigen P.f (catalogue number 05FK90,
Standard Diagnostics Inc. South Korea) product [11].
The analysis also revealed that even when both the
pan and P. falciparum bands were positive, the band
intensity of the pan band was generally lower than the
Pf band, irrespective of the parasite density. At the lower
parasite density of 200 parasites/μL, 65% of the positive pan
bands had an intensity of 1. This proportion reduced to
16% when samples contained 2,000 or 5,000 parasites/μL.
Thus even when the pan band is positive, it is often faint.
The RDT testing conducted for the WHO-FIND product
testing programme occurs at the CDC in ideal conditions
which assists with the identification of these weak positive
results. However faint bands are often difficult to see and
may well be missed by health workers working in reduced
lighting conditions or with reduced visual acuity [12,13].
This would inflate the proportion of RDTs having a positive
HRP2 band and negative pan band.
There are several possible reasons for the observed
differences in positivity and intensity of HRP2 Pf bands
compared to pLDH pan bands. First, the relative
abundance of HRP2 and pLDH may differ within
parasites. The samples used within the current study
had wide but similar ranges of concentrations for
HRP2 and pLDH and there was a significant positive
correlation between the two antigen concentrations.
Hence it does not appear that gross differences in
antigen concentration were the cause of the disparity
in test band performance against P. falciparum.
The second possible reason is related to differences in
avidity of the antigen for binding the antibodies bound
to the RDT test lines. The current results indicate that
approximately 4 ng/mL of HRP2 is required to obtain a
positive HRP2 band in over 95% of tests, compared to over
45 ng/mL for pan-pLDH. This difference in concentration
aligns with the HRP2 antigen having multiple binding
epitopes due to its repeat structure, compared to pLDH,
which is a single epitope. Lee et al. [14] reported the most
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Figure 5 Relationship between antigen concentration and RDT
test band positivity for HRP2 (top) and pan-pLDH (bottom).
Only samples used to test 10 or more individual RDTs are displayed.
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frequent HPR2 motifs occurred within the HRP2 sequence
with a frequency of 8–25, depending on the motif
and specific sequence. This frequency aligns approximately
with the differences in threshold concentration observed
here. Thus, it appears that the difference in antibody-
binding avidity between HRP2 and pLDH may be a cause
of differences in sensitivity of the respective test bands. It is
unlikely that the ordering of the bands on the strip
accounts for diminished performance of the pan test
bands because for all except two tests included in this
analysis the pan test band is the farthest from the
origin and this position is advantageous as the flow
rate at which the analyte passes the capture reagent line is
slower; and the effective concentration of analyte in the
sample is higher [15].
Many studies have been conducted to assess the per-
formance of specific malaria RDTs in different settings [1].
However few have directly compared HRP2-detecting
RDTs to pLDH-detecting RDTs, and examined potential
reasons for the differences in the two types of tests.
A longitudinal study in Uganda identified that HRP2-
detecting RDTs provide better detection of parasites
at low densities compared to pLDH-detecting RDTs,
but have lower specificity due to the slower clearance
of HRP2 antigenaemia from the blood circulation
[16]. Differences have also been observed in performance
between regions with different transmission intensities,
and this difference was attributed to the superior ability of
HRP2-detecting RDTs over pLDH-detecting RDTs to
detect sub-patent parasitaemia [17]. These results,
although obtained by comparing different RDTs that both
detect P. falciparum, appear relevant for the combination
tests with antibodies against these two antigens. It
would be possible to distinguish between persistent
HRP2 antigenaemia and viable falciparum parasitaemia in
a given blood sample by comparing the results of an
HRP2-based RDT with a separate, equally well-performing
RDT containing a falciparum pLDH band, but that is not a
viable proposition for field use.
Therefore, the problem remains of how to clinically
manage a febrile patient with a history of recent anti-
malarial treatment who returns a positive HRP2 band,
but a negative pLDH band on a combination RDT. This
can result from persistent antigenaemia or malaria
re-infection or recrudescence (treatment failure).
Treatment failure may result from drug resistance or
inadequate exposure to the drug due to sub-optimal dosing,
poor adherence, vomiting, unusual pharmacokinetics in an
individual or substandard medicines. It is important to
determine from the patient’s history whether he or she
vomited the previous treatment or did not complete the full
course of treatment. These cases need to be treated
again with the artemisinin-combination therapy (ACT)
recommended as first-line in the area.
If the patient’s history reveals that he/she has taken the
full and correctly dosed treatment course, the possibility
of true treatment failure can only be excluded by referring
the patient to a facility with good quality microscopy.
Referral may be necessary anyway to obtain second-line
treatment. In individual patients, it may not be possible to
distinguish recrudescence from re-infection, although lack
of resolution of fever and parasitaemia (on microscopy) or
their recurrence within four weeks of treatment are
considered failures of treatment with the currently
recommended ACT. For these cases the recommended
second-line treatment is an alternative ACT known to be
effective in the region. In addition to the above guidance,
in all cases the health provider should always consider
other diagnoses and follow closely for a clinical response.
Recurrence of fever and parasitaemia more than
four weeks after treatment may be due to either
recrudescence or a new infection. The distinction can
only be made by genotyping of parasites from the initial
and the recurrent infections. As parasite genotyping is not
routinely used in patient management, then all presumed
treatment failures after four weeks of initial treatment
should be considered new infections and be treated with
the first-line ACT.
Ultimately, the results from this study clearly show
that in the setting of active (untreated) malaria infection,
it is common for HRP2/pan-pLDH combination tests to
return a positive HRP2 band combined with a negative
pan-pLDH band at low parasite densities, and when
both bands are positive, often the pan band is faint even
at densities of 2,000 parasites/μL. Therefore it would be
dangerous to interpret the presence of a HRP2 band in
the absence of a pan band as being caused solely by
persistent antigenaemia in a clinical setting. Only
when the sensitivity of the pLDH-detecting pan band
is improved to have the comparable reactivity as the
HRP2 band for detecting P. falciparum could persistent
antigenaemia be confidently attributed as the cause of
HRP2-positive, pan-negative RDT results.
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